相似文献
1
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
Cancer Cell. 2018 Mar 12;33(3):527-541.e8. doi: 10.1016/j.ccell.2018.01.018. Epub 2018 Mar 1.
2
Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Clin Orthop Relat Res. 2014 Mar;472(3):874-82. doi: 10.1007/s11999-013-3065-9.
3
The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
Cancer Res. 2006 Oct 1;66(19):9474-82. doi: 10.1158/0008-5472.CAN-05-3726.
4
The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.
Oncogene. 2016 Sep 22;35(38):5021-32. doi: 10.1038/onc.2016.38. Epub 2016 Mar 7.
5
Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.
Int J Oncol. 2010 Apr;36(4):823-31. doi: 10.3892/ijo_00000559.
6
Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
Cell. 2013 Mar 28;153(1):71-85. doi: 10.1016/j.cell.2013.02.036.
7
Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.
Mod Pathol. 2007 Apr;20(4):482-96. doi: 10.1038/modpathol.3800761. Epub 2007 Mar 2.
8
Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
Nat Struct Mol Biol. 2023 Nov;30(11):1640-1652. doi: 10.1038/s41594-023-01096-3. Epub 2023 Sep 21.
9
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
Cancer Cell. 2018 Jun 11;33(6):1128-1141.e7. doi: 10.1016/j.ccell.2018.05.002. Epub 2018 May 31.
10
Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes.
Nat Cell Biol. 2013 Apr;15(4):373-84. doi: 10.1038/ncb2702. Epub 2013 Mar 17.
引用本文的文献
1
Cell Settling, Migration, and Stochastic Cancer Gene Expression Suggest Potassium Membrane Flux May Initiate pH Reversal.
Biomolecules. 2025 Aug 16;15(8):1177. doi: 10.3390/biom15081177.
2
Overexpression of oncogenic polo-like kinase 1 disrupts the invasiveness, cell cycle, and apoptosis in synovial sarcoma.
J Transl Med. 2025 Jun 20;23(1):691. doi: 10.1186/s12967-025-06740-8.
3
Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas.
Nat Commun. 2025 Jun 16;16(1):5283. doi: 10.1038/s41467-025-60519-5.
4
Targeted disruption of PRC1.1 complex enhances bone remodeling.
Nat Commun. 2025 May 8;16(1):4294. doi: 10.1038/s41467-025-59638-w.
5
Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma.
Sci Adv. 2025 Apr 25;11(17):eads7876. doi: 10.1126/sciadv.ads7876. Epub 2025 Apr 23.
6
SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression.
Cell Biol Toxicol. 2024 Dec 21;41(1):8. doi: 10.1007/s10565-024-09952-8.
7
Condensate remodeling reorganizes innate SS18 in synovial sarcomagenesis.
Oncogenesis. 2024 Oct 29;13(1):38. doi: 10.1038/s41389-024-00539-w.
8
Molecular Profiling Defines Three Subtypes of Synovial Sarcoma.
Adv Sci (Weinh). 2024 Nov;11(41):e2404510. doi: 10.1002/advs.202404510. Epub 2024 Sep 10.
9
Combination of HDAC and FYN inhibitors in synovial sarcoma treatment.
Front Cell Dev Biol. 2024 Jul 9;12:1422452. doi: 10.3389/fcell.2024.1422452. eCollection 2024.
10
Chromatin remodellers as therapeutic targets.
Nat Rev Drug Discov. 2024 Sep;23(9):661-681. doi: 10.1038/s41573-024-00978-5. Epub 2024 Jul 16.
本文引用的文献
1
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
Cell. 2017 Nov 2;171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014.
2
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.
Nat Med. 2017 Mar;23(3):386-395. doi: 10.1038/nm.4273. Epub 2017 Jan 30.
3
Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states.
Nat Genet. 2017 Feb;49(2):213-222. doi: 10.1038/ng.3734. Epub 2016 Dec 12.
4
Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin.
Nat Genet. 2017 Feb;49(2):282-288. doi: 10.1038/ng.3735. Epub 2016 Dec 12.
5
BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities.
Am J Surg Pathol. 2016 Dec;40(12):1670-1678. doi: 10.1097/PAS.0000000000000697.
6
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.
Cancer Discov. 2016 Aug;6(8):914-29. doi: 10.1158/2159-8290.CD-16-0154. Epub 2016 Jun 3.
7
Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay.
Oncotarget. 2016 Jun 7;7(23):34384-94. doi: 10.18632/oncotarget.8882.
8
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.
Cell. 2016 Feb 25;164(5):1060-1072. doi: 10.1016/j.cell.2016.01.015.
9
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
J Clin Invest. 2016 Mar 1;126(3):905-20. doi: 10.1172/JCI84014. Epub 2016 Jan 25.
10
Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas.
Am J Surg Pathol. 2016 Apr;40(4):433-42. doi: 10.1097/PAS.0000000000000591.
Zotero 插件